HDAC1 / 2 selective inhibitor and use thereof
By designing and synthesizing compounds with high selectivity of HDAC1/2, the problem of adverse reactions of existing HDAC1/2 selective inhibitors in clinical applications has been solved, and the excellent efficacy and safety of the compounds have been achieved, which is suitable for treatment or prevention cancer.
Patent Information
- Application Number
- PCT/CN2024/093036
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2024-05-14
- Publication Date
- 2024-11-21
AI Technical Summary
Existing HDAC1/2 selective inhibitors have serious adverse reactions in clinical applications, including hematological and systemic adverse reactions, affecting the safety and effectiveness of the drug.
A series of compounds with high selectivity for HDAC1/2 have been developed, and the efficacy and safety of the compounds are optimized through specific chemical structural design and synthesis methods, providing drugs for the treatment or prevention of cancer.
Excellent efficacy and safety were demonstrated in in vitro and in vivo experiments, significantly improving the safety and effectiveness of existing drugs and reducing the occurrence of adverse reactions.
Smart Images

Figure CN2024093036_21112024_PF_FP_ABST
Abstract
Description
HDAC1 / 2 selective inhibitors and uses thereof
[0001] This application claims priority to Chinese patent application No. 202310547297.2, filed May 15, 2023. This application incorporates the entire text of the aforementioned Chinese patent application. Technical Field
[0002] The present invention belongs to the field of medicinal chemistry, and more specifically, relates to a class of HDAC1 / 2 selective inhibitors, a preparation method thereof, and the use of such compounds in preparing drugs for treating or preventing cancer. Background Art
[0003] Histone deacetylases (HDACs) are a class of proteases whose acetylation and deacetylation of histones in chromatin are key regulators of gene expression. Abnormal gene expression underlies the molecular biological basis of tumors and some genetic and metabolic diseases. The degree of histone acetylation is coordinated by histone acetylases (HATs) and histone deacetylases (HDACs). When HDACs are overexpressed and recruited by transcription factors, they lead to the abnormal repression of specific genes, causing tumors and other diseases.
[0004] HDACs are a large family of enzymes, with four known classes and 18 different subtypes. Class I includes four subtypes: HDAC1, 2, 3, and 8; Class II includes six subtypes: HDAC4, 5, 6, 7, 9, and 10 (of which 4, 5, 7, and 9 belong to Class IIa, and 6 and 10 belong to Class IIb); Class IV contains only one subtype, HDAC11, which shares some homology with the first two classes; and Class III includes seven subtypes, SIRT1-7, which lack structural homology with the first three classes.
[0005] According to published clinical results, although HDAC1, 2, and 3 selective inhibitors such as MS275 (Entinostat), cedaranid (already marketed), and CXD101 have significantly fewer toxic side effects than Pan HDAC inhibitors such as vorinostat, romidepsin, belinostat, and panobinostat, serious adverse reactions have still been observed in clinical trials, including hematological adverse reactions, systemic adverse reactions including fatigue and fever, gastrointestinal adverse reactions, metabolic and nutritional system adverse reactions, and other adverse reactions such as dizziness and rash.
[0006] Summary of the Invention
[0007] The present invention provides a series of compounds with high selectivity for HDAC1 / 2. They have demonstrated excellent efficacy and safety in various in vitro and in vivo evaluation experiments, and are of great clinical significance for improving the efficacy and safety of existing drugs.
[0008] Specifically, the present invention provides a compound represented by general formula (1) or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates:
[0009] In the general formula (1):
[0010] X is -NH2, -OH;
[0011] Cy is (C6-C14)aryl or (5-14 membered)heteroaryl, wherein said (C6-C14)aryl or (5-14 membered)heteroaryl may be independently optionally substituted by 1, 2, 3 or 4 R 5 replace;
[0012] Ring A is (C6-C14)aryl, (5-14 membered)heteroaryl, (C3-C14)cycloalkyl or (3-14 membered)heterocycloalkyl;
[0013] R 1 is H, D, halogen;
[0014] R 2 is H, D, halogen, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl;
[0015] R 3 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl, wherein said (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl may be independently optionally substituted by 1, 2, 3 or 4 R a replace;
[0016] R 4 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl; wherein the (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl can be independently optionally substituted by 1, 2, 3 or 4 R b replace;
[0017] or R3 and R 4 The S atom to which it is connected forms a (3-16 membered) heterocycloalkyl group, wherein the (3-16 membered) heterocycloalkyl group may be independently optionally substituted with 1, 2, 3 or 4 R 6 replace;
[0018] R 5 H, D, halogen, hydroxyl, amino, cyano, nitro, -OR a 、-NR a R b 、-C(O)R a 、-CO2R a 、-(CH2) m R a 、-(CH2) m CO2R a 、-(CH2) m -CONR a R b 、-S(O) p R a 、-S(O) p NR a R b 、-CONR a R b 、-C(=NR a )-NR a R b 、-NR a COR b 、-CR a CONR a R b 、-NR a CO2R a 、-NR a S(O) p NR a R b 、-NR a S(O) p R a 、-P(O) p R a R b, (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocycloalkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocycloalkyl, -(C1-C8)alkylene-(C6-C14)aryl, -(C1-C8)alkylene-(5-14-membered)heteroaryl, wherein the (C1-C8)alkylene 8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocycloalkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocycloalkyl, -(C1-C8)alkylene-(C6-C14)aryl, -(C1-C8)alkylene-(5-14-membered)heteroaryl may each independently be optionally substituted by 1, 2, 3 or 4 R c replace;
[0019] R 6 H, D, halogen, hydroxyl, amino, cyano, nitro, -OR a 、-NR a R b 、-C(O)R a 、-CO2R a 、-(CH2) m R a 、-(CH2) m CO2R a 、-(CH2) m -CONR a R b 、-S(O) p R a 、-S(O) p NR a R b 、-CONR a R b 、-C(=NR a )-NR a R b 、-NR a COR b 、-CR a CONR a R b 、-NR a CO2R a 、-NR a S(O)p NR a R b 、-NR a S(O) p R a 、-P(O) p R a R b , (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocycloalkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocycloalkyl, -(C1-C8)alkylene-(C6-C14)aryl, -(C1-C8)alkylene-(5-14-membered)heteroaryl, wherein the (C1-C8)alkylene 8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocycloalkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocycloalkyl, -(C1-C8)alkylene-(C6-C14)aryl, -(C1-C8)alkylene-(5-14-membered)heteroaryl may each independently be optionally substituted by 1, 2, 3 or 4 R c Replace; or when 2 R 6 When attached to the same atom, the two R 6 The atoms to which it is attached may form an oxo group, a (C3-C6)cycloalkyl group or a (3-6 membered)heterocycloalkyl group;
[0020] R a and R bEach is independently -H, -D, halogen, hydroxy, amino, cyano, nitro, (C1-C8) alkyl, (C1-C8) alkoxy, (C1-C8) haloalkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C14) cycloalkyl, (3-14 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C8) alkylene-(C3-C14) cycloalkyl, -(C1-C8) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C8) alkylene-(C6-C14) aryl, -(C1-C8) alkylene-(5-14 membered) hetero aryl, wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocycloalkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocycloalkyl, -(C1-C8)alkylene-(C6-C14)aryl, -(C1-C8)alkylene-(5-14-membered)heteroaryl can each be independently optionally substituted by 1, 2, 3 or 4 R c Replace; or when 2 R a When attached to the same atom, the two R a Can form an oxo group; or when 2 R b When attached to the same atom, the two R b Can form an oxo group; or R attached to the same atom a and R b The atoms to which it is attached together form a (5-7 membered) heterocycloalkyl or (C3-C9) cycloalkyl, wherein said (5-7 membered) heterocycloalkyl or (C3-C9) cycloalkyl are each independently optionally substituted by 1, 2, 3 or 4 R c replace;
[0021] R c is -H, -D, halogen, hydroxy, amino, cyano, nitro, (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocycloalkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C1-C8)alkoxy, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocycloalkyl, -(C1-C8)alkylene-(C6-C14)aryl, -(C1-C8)alkylene-(5-14-membered)heteroaryl; or when 2 R cWhen attached to the same atom, the two R c It can form an oxo group, (C3-C6) cycloalkyl group or (3-6 membered) heterocycloalkyl group;
[0022] m, n, and p are integers of 0, 1, or 2.
[0023] In another preferred technical solution, in the compound of the general formula (1), X is -NH2, -OH; X is preferably -NH2.
[0024] In another preferred technical solution, in the compound of the general formula (1), ring A is (C6-C10)aryl, (5-10 membered)heteroaryl, (C3-C12)cycloalkyl or (3-12 membered)heterocycloalkyl; ring A is preferably phenyl, (5-7 membered)heteroaryl, (C5-C7)cycloalkyl; ring A is more preferably phenyl, pyridyl or cyclohexyl.
[0025] In another preferred embodiment, in the compound of formula (1), Cy is a (C6-C10) aryl or a (5-12 membered) heteroaryl, wherein the (C6-C10) aryl or (5-12 membered) heteroaryl can be independently optionally replaced by 1, 2, 3 or 4 R 5 Substitution; Cy is preferably phenyl, (5-7 membered) heteroaryl.
[0026] In another preferred technical solution, wherein in the compound of formula (1), Cy is phenyl or (5-6 membered) heteroaryl, preferably
[0027] In another preferred technical solution, wherein in the compound of formula (1), R 5 H, D, halogen, hydroxyl, amino, cyano, nitro, -OR a 、-NR a R b 、-C(O)R a 、-CO2R a 、-(CH2) m R a 、-(CH2) m CO2R a 、-(CH2) m CONR a R b 、-S(O) p R a 、-S(O) p NR a R b 、-CONR a R b 、-C(=NR a )-NRa R b 、-NR a COR b 、-CR a CONR a R b 、-NR a CO2R a 、-NR a S(O) p NR a R b 、-NR a S(O) p R a 、-P(O) p R a R b , (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C12) cycloalkyl, (3-12 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C6) alkylene-(C3-C14) cycloalkyl, -(C1-C6) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C6) alkylene-(C6-C14) aryl, -(C1-C6) alkylene-(5-14 membered) heteroaryl, wherein the (C1-C6) 6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C12)cycloalkyl, (3-12 membered)heterocycloalkyl, (C6-C14)aryl, (5-14 membered)heteroaryl, -(C1-C6)alkylene-(C3-C14)cycloalkyl, -(C1-C6)alkylene-(3-14 membered)heterocycloalkyl, -(C1-C6)alkylene-(C6-C14)aryl, -(C1-C6)alkylene-(5-14 membered)heteroaryl may each independently be optionally substituted by 1, 2, 3 or 4 R c Replacement; R 5 Preferably H, D, halogen, hydroxy, amino, cyano, nitro, -OR a 、-NR a R b 、-CONR a R b 、-P(O) p R a R b 、-S(O) p R a , (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C2-C4 alkenyl, (C2-C4) alkynyl, (C3-C7) cycloalkyl, (3-7 membered) heterocycloalkyl.
[0028] In another preferred technical solution, wherein the compound of the general formula (1), wherein R 5 is H, D, F, Cl, -CN, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, (C3-C6) cycloalkyl, R 5 Preferably H, D, F, Cl, -CN, -CH3, -CF3, -OCH3 or
[0029] In another preferred technical solution, wherein in the compound of formula (1), R 1 For H, D, F, Cl, Br, I; R 1 Preferred are H, D, and F.
[0030] In another preferred technical solution, wherein in the compound of formula (1), R 2 R is H, D, F, Cl, Br, I, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl; 2 Preferred are H, D, and F.
[0031] In another preferred technical solution, wherein in the compound of formula (1), R 3 is (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl, wherein said (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl can be independently optionally substituted by 1, 2, 3 or 4 R a Replacement; R 3 Preferably, R is (C1-C4)alkyl, (C1-C4)alkoxy, or (C1-C4)halogenated alkyl; 3 More preferred are methyl, ethyl and methoxymethyl.
[0032] In another preferred technical solution, wherein in the compound of formula (1), R 4is (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl, wherein said (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl can be independently optionally substituted by 1, 2, 3 or 4 R b Replacement; R 4 Preferably, R is (C1-C4)alkyl, (C1-C4)alkoxy, or (C1-C4)halogenated alkyl; 4 More preferred are methyl, ethyl and methoxymethyl.
[0033] In another preferred technical solution, wherein in the compound of formula (1), R 3 and R 4 The S atom to which it is attached forms a (3-14 membered) heterocycloalkyl group, wherein the (3-14 membered) heterocycloalkyl group may be independently optionally substituted with 1, 2, 3 or 4 R 6 replace.
[0034] In another preferred technical solution, wherein in the compound of formula (1), R 3 and R 4 The S atom to which it is connected forms a (4-6 membered) monocyclic heterocycloalkyl group containing 1 or 2 groups selected from N, S or O, or a (7-9 membered) bicyclic spirocyclic heterocycloalkyl group containing 1 or 2 groups selected from N, S or O, wherein the (4-6 membered) monocyclic heterocycloalkyl group or the (7-9 membered) bicyclic spirocyclic heterocycloalkyl group can be independently optionally replaced by 1, 2, 3 or 4 R 6 replace.
[0035] In another preferred technical solution, wherein in the compound of formula (1), R 6 H, D, halogen, hydroxyl, amino, cyano, nitro, -OR a 、-NR a R b 、-C(O)R a 、-CO2R a 、-(CH2) m R a 、-(CH2) m CO2R a 、-(CH2) m CONR a R b 、-S(O) p R a 、-S(O) p NR a Rb 、-CONR a R b 、-C(=NR a )-NR a R b 、-NR a COR b 、-CR a CONR a R b 、-NR a CO2R a 、-NR a S(O) p NR a R b 、-NR a S(O) p R a 、-P(O) p R a R b , (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C14) cycloalkyl, (3-14 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C6) alkylene-(C3-C14) cycloalkyl, -(C1-C6) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C6) alkylene-(C6-C14) aryl, -(C1-C6) alkylene-(5-14 membered) heteroaryl, wherein the (C1-C6) 6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocycloalkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C6)alkylene-(C3-C14)cycloalkyl, -(C1-C6)alkylene-(3-14-membered)heterocycloalkyl, -(C1-C6)alkylene-(C6-C14)aryl, -(C1-C6)alkylene-(5-14-membered)heteroaryl may each independently be optionally substituted by 1, 2, 3 or 4 R c Replacement; R 6 Preferably H, D, halogen, hydroxy, amino, cyano, -OR a 、-NR a R b, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, -(C1-C4) alkylene-(C3-C7) cycloalkyl, -(C1-C4) alkylene-(3-7 membered) heterocycloalkyl, -(C1-C4) alkylene-(5-7 membered) heteroaryl, wherein said (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, -(C1-C4) alkylene-(C3-C7) cycloalkyl, -(C1-C4) alkylene-(3-7 membered) heterocycloalkyl, -(C1-C4) alkylene-(5-7 membered) heteroaryl can be independently optionally replaced by 1, 2, 3 or 4 R c Replace; or when 2 R 6 When attached to the same atom, the two R 6 The atom to which it is attached can form an oxo group.
[0036] In another preferred technical solution, wherein in the compound of formula (1), R 6 is H, D, F, Cl, hydroxyl, amino, cyano, methyl, ethyl, -NH(CH3), -N(CH3)2, -CD3, -C(O)CH3 or
[0037] In another preferred technical solution, wherein in the compound of formula (1), R a and R b Each is independently -H, -D, halogen, hydroxy, amino, cyano, nitro, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C14) cycloalkyl, (3-14 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C6) alkylene-(C3-C14) cycloalkyl, -(C1-C6) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C6) alkylene-(C6-C14) aryl, -(C1-C6) alkylene-(5-14 membered) hetero aryl, wherein the (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocycloalkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C6)alkylene-(C3-C14)cycloalkyl, -(C1-C6)alkylene-(3-14-membered)heterocycloalkyl, -(C1-C6)alkylene-(C6-C14)aryl, -(C1-C6)alkylene-(5-14-membered)heteroaryl can each be independently optionally replaced by 1, 2, 3 or 4 R c Replace; or when 2 R a When attached to the same atom, the two Ra Can form an oxo group; or when 2 R b When attached to the same atom, the two R b Can form an oxo group; R a and R b Each is independently preferably H, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C3-C7) cycloalkyl, (3-7 membered) heterocycloalkyl, (C6-C10) aryl, (5-7 membered) heteroaryl, wherein the (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C3-C7) cycloalkyl, (3-7 membered) heterocycloalkyl, (C6-C10) aryl, (5-7 membered) heteroaryl can be independently optionally replaced by 1, 2, 3 or 4 R c replace.
[0038] In another preferred embodiment, in the compound of the general formula (1), R a and R b The atoms to which it is connected together form a (5-7 membered) heterocycloalkyl or (C3-C9) cycloalkyl, wherein the (5-7 membered) heterocycloalkyl or (C3-C9) cycloalkyl is independently optionally substituted by 1, 2, 3 or 4 R c replace.
[0039] In another preferred technical solution, wherein in the compound of formula (1), R c is -H, -D, halogen, hydroxy, amino, cyano, nitro, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C14) cycloalkyl, (3-14 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C6) alkylene-(C1-C8) alkoxy, -(C1-C6) alkylene-(C3-C14) cycloalkyl, -(C1-C6) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C6) alkylene-(C6-C14) aryl, -(C1-C6) alkylene-(5-14 membered) heteroaryl; or when 2 R c When attached to the same atom, the two R c Can form an oxo group; R c Preferred are H, D, halogen, hydroxy, amino, cyano, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C3-C7) cycloalkyl, and (3-7 membered) heterocycloalkyl.
[0040] In another embodiment of the present invention, the compound of formula (1) has one of the following structures:
[0041] Another object of the present invention is to provide a pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent and / or excipient, and a compound of the general formula (1) of the present invention, or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates as active ingredients.
[0042] Another object of the present invention is to provide the use of the compound represented by general formula (1) of the present invention, or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, or the pharmaceutical composition thereof, for preparing a drug for treating, regulating or preventing diseases associated with HDAC1 / 2 inhibitors. The disease is preferably cancer, and the cancer is a blood cancer or a solid tumor.
[0043] It is to be understood that both the foregoing general description and the following detailed description of the present invention are exemplary and explanatory and are intended to provide further explanation of the invention as claimed.
[0044] Synthesis of compounds
[0045] The following specifically describes the preparation methods of the compound of general formula (1) of the present invention, but these specific methods do not constitute any limitation to the present invention.
[0046] The compounds of formula (1) described above can be synthesized using standard synthetic techniques or known techniques in combination with the methods described herein. In addition, the solvents, temperatures and other reaction conditions mentioned herein may vary. The starting materials used in the synthesis of the compounds can be synthesized or obtained from commercial sources. The compounds described herein and other related compounds having different substituents can be synthesized using known techniques and starting materials, including those found in March, ADVANCED ORGANIC CHEMISTRY 4 th Ed., (Wiley 1992); Carey and Sundberg, ADVANCED ORGANIC CHEMISTRY 4 th Ed., Vols.A and B (Plenum 2000, 2001), Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS 3 rd Ed., (Wiley 1999). The general methods for the preparation of compounds can be modified by using appropriate reagents and conditions to introduce various groups into the formulae provided herein.
[0047] On the one hand, the compounds described herein are prepared according to methods known in the art. However, the conditions of the methods, such as reactants, solvents, bases, the amounts of the compounds used, reaction temperatures, reaction times, etc., are not limited to the following explanations. The compounds of the present invention can also be conveniently prepared by optionally combining various synthetic methods described in this specification or known in the art, and such combinations can be easily performed by those skilled in the art. On the one hand, the present invention also provides a method for preparing the compound of the general formula (1), wherein the compound of the general formula (1) can be prepared using the following general reaction schemes 1-3:
[0048] General reaction scheme 1
[0049] Among them, A, Cy, R 1 、R 2 、R 3 、R 4 , X, m, and n are as defined above, and PG represents a commonly used amino or hydroxyl protecting group (e.g., Boc, Cbz, Bz, Fmoc, Bn, etc.). As shown in General Reaction Scheme 1, compound A1 and raw material A2 undergo condensation reaction to produce compound A3, which is then subjected to coupling reaction and conventional deprotection reaction to produce the target compound (1).
[0050] General reaction scheme 2
[0051] Among them, A, Cy, R 1 、R 2 、R 3 、R 4 , X, m, and n are as defined above, and PG represents a commonly used amino or hydroxyl protecting group (e.g., Boc, Cbz, Bz, Fmoc, Bn, etc.). As shown in General Reaction Scheme 2, compound B1 undergoes a coupling reaction to obtain compound B2, which is then condensed with raw material A1, followed by conventional deprotection reaction to obtain the target compound (1).
[0052] General reaction scheme 3
[0053] Among them, A, Cy, R 1 、R 2 、R 3 、R 4 , X, m, and n are as defined above; PG represents a commonly used amino or hydroxyl protecting group (e.g., Boc, Cbz, Bz, Fmoc, Bn, etc.); and Y represents a leaving group such as Br, I, or OTf. As shown in General Reaction Scheme 3, compound C1 and raw material C2 are condensed to obtain target compound C3. Compound C3 and compound C4 are coupled and subjected to conventional deprotection reaction to obtain target compound (1).
[0054] Further forms of compounds
[0055] "Pharmaceutically acceptable" as used herein refers to a substance, such as a carrier or diluent, that does not abrogate the biological activity or properties of the compound and is relatively non-toxic, i.e., a substance that does not cause undesirable biological effects or interact in a deleterious manner with any of its components when administered to a subject.
[0056] The term "pharmaceutically acceptable salt" refers to a form of a compound that does not cause significant irritation to the organism to which it is administered and does not abrogate the biological activity and properties of the compound. In certain specific aspects, pharmaceutically acceptable salts are obtained by reacting a compound of the formula with an acid or base, wherein the acid or base includes, but is not limited to, those found in Stahl and Wermuth, Handbook of Pharmaceutical Salts: Properties, Selection, and Use 1. st Acids and Bases in Ed., (Wiley, 2002).
[0057] It should be understood that references to pharmaceutically acceptable salts include solvent-added forms or crystallized forms, particularly solvates or polymorphs. Solvates contain stoichiometric or non-stoichiometric amounts of solvent and are selectively formed during crystallization with pharmaceutically acceptable solvents such as water, ethanol, etc. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is ethanol. Solvates of compounds of formula (1) are conveniently prepared or formed according to the methods described herein. For example, hydrates of compounds of formula (1) are conveniently prepared by recrystallization from a mixed solvent of water / organic solvent, using organic solvents including, but not limited to, tetrahydrofuran, acetone, ethanol or methanol. In addition, the compounds mentioned herein can exist in unsolvated and solvated forms. In general, for the purposes of the compounds and methods provided herein, the solvated forms are considered to be equivalent to the unsolvated forms.
[0058] In other embodiments, the compound of formula (1) is prepared in different forms, including but not limited to, amorphous, crushed and nano-particle forms. In addition, the compound of formula (1) includes crystalline forms and can also be polymorphic. Polymorphs include different lattice arrangements of the same elemental composition of the compound. Polymorphs generally have different X-ray diffraction spectra, infrared spectra, melting points, density, hardness, crystal form, optical and electrical properties, stability and solubility. Different factors such as recrystallization solvent, crystallization rate and storage temperature may cause a single crystalline form to dominate.
[0059] In another aspect, compounds of formula (1) may have chiral centers and / or axial chirality and thus occur as racemates, racemic mixtures, single enantiomers, diastereomeric compounds and single diastereomers, and cis-trans isomers. Each chiral center or axial chirality will independently produce two optical isomers, and all possible optical isomers and diastereomeric mixtures as well as pure or partially purified compounds are included within the scope of the present invention. The present invention is intended to include all such isomeric forms of these compounds.
[0060] The compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound. For example, the compounds may be labeled with radioactive isotopes, such as tritium ( 3 H), iodine-125 ( 125 I) and C-14( 14 C). For example, deuterated compounds can be formed by replacing hydrogen atoms with heavy hydrogen. The bond formed by deuterium and carbon is stronger than the bond formed by ordinary hydrogen and carbon. Compared with non-deuterated drugs, deuterated drugs generally have advantages such as reduced toxic side effects, increased drug stability, enhanced efficacy, and prolonged drug half-life in vivo. All isotopic variations of the compounds of the present invention, whether radioactive or not, are included within the scope of this invention.
[0061] Unless otherwise specified, any reference to an atom in the compounds of the present invention refers to its stable atomic isotope. Unless otherwise specified, when a position in a molecular structure is designated as "H" or "hydrogen," such position should be understood to have the natural abundance of the hydrogen isotope. Similarly, when a position is designated as "D" or "deuterium," such position should be understood to have a deuterium isotope abundance at least 3000 times its natural abundance (the natural abundance of the deuterium isotope is 0.015%).
[0062] More preferably, the deuterium atom abundance at each deuterated site of the deuterated compound of the present invention is at least 3500 times its natural abundance (52.2% deuterium atom enrichment). More preferably, it is at least 4500 times (67.5% deuterium atom enrichment). More preferably, it is at least 5000 times (75% deuterium atom enrichment). More preferably, it is at least 6000 times (90% deuterium atom enrichment). More preferably, it is at least 6333 times (95% deuterium atom enrichment). More preferably, it is at least 6466.7 times (97% deuterium atom enrichment). More preferably, it is at least 6600 times (99% deuterium atom enrichment). More preferably, it is at least 6633.3 times (99.5% deuterium atom enrichment).
[0063] the term
[0064] Unless otherwise indicated, the terms used in this application, including the specification and claims, are defined as follows. It should be noted that, throughout the specification and the appended claims, the singular forms "a," "an," and "an" include plural referents unless the context clearly indicates otherwise. Conventional methods, such as mass spectrometry, nuclear magnetic resonance, HPLC, protein chemistry, biochemistry, recombinant DNA technology, and pharmacology, are employed unless otherwise indicated. Throughout this application, the use of "or" or "and" means "and / or," unless otherwise indicated.
[0065] Unless otherwise specified, "alkyl" refers to a saturated aliphatic hydrocarbon group, including straight and branched groups of 1 to 6 carbon atoms. Preferred are lower alkyl groups containing 1 to 4 carbon atoms, such as methyl, ethyl, propyl, 2-propyl, n-butyl, isobutyl, and tert-butyl. More preferred are lower alkyl groups containing 1 to 3 carbon atoms, such as methyl, ethyl, propyl, and 2-propyl. As used herein, "alkyl" includes unsubstituted and substituted alkyl groups, especially alkyl groups substituted with one or more halogens. Preferred alkyl groups are selected from CH3, CH3CH2, CF3, CHF2, CF3CH2, CF3(CH3)CH, i Pr, n Pr, i Bu, n Bu or t Bu.
[0066] Unless otherwise specified, "alkylene" refers to a divalent alkyl group as defined above. Examples of alkylene groups include, but are not limited to, methylene and ethylene.
[0067] Unless otherwise specified, "alkenyl" refers to an unsaturated aliphatic hydrocarbon group containing a carbon-carbon double bond, including straight or branched groups of 1 to 14 carbon atoms. Preferred are lower alkenyl groups containing 1 to 4 carbon atoms, such as ethenyl, 1-propenyl, 1-butenyl, or 2-methylpropenyl. More preferred are lower alkenyl groups containing 1 to 2 carbon atoms.
[0068] Unless otherwise specified, "alkenylene" refers to a divalent alkenyl group as defined above.
[0069] Unless otherwise specified, "alkynyl" refers to an unsaturated aliphatic hydrocarbon group containing a carbon-carbon triple bond, including straight-chain and branched groups having 1 to 14 carbon atoms. Preferred are lower alkynyl groups having 1 to 4 carbon atoms, such as ethynyl, 1-propynyl, or 1-butynyl. More preferred are lower alkynyl groups having 1 to 2 carbon atoms.
[0070] Unless otherwise specified, "alkynylene" refers to a divalent alkynyl group as defined above.
[0071] Unless otherwise specified, "cycloalkyl" refers to a non-aromatic hydrocarbon ring system (monocyclic, bicyclic or polycyclic), preferably containing 3 to 14 ring carbon atoms (C 3-14In some embodiments, the cycloalkyl group has 3-10 ring carbon atoms (C 3-10 In some embodiments, a cycloalkyl group has 3-8 ring carbon atoms (C 3-8 In some embodiments, the cycloalkyl group has 3-7 ring carbon atoms (C 3-7 In some embodiments, the cycloalkyl group has 3-6 ring carbon atoms (C 3-6 In some embodiments, the cycloalkyl group has 4-6 ring carbon atoms (C 4-6 In some embodiments, the cycloalkyl group has 5-6 ring carbon atoms (C 5-6 In some embodiments, a cycloalkyl group has 5-10 ring carbon atoms (C 5-10 Cycloalkyl). If the carbocyclic ring contains at least one double bond, the partially unsaturated cycloalkyl group may be referred to as a "cycloalkenyl group," or if the carbocyclic ring contains at least one triple bond, the partially unsaturated cycloalkyl group may be referred to as a "cycloalkynyl group." Cycloalkyl groups may include monocyclic or polycyclic (e.g., having 2, 3, or 4 fused rings) groups and spirocycles. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is bicyclic. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is tricyclic. The ring-forming carbon atoms of the cycloalkyl group may optionally be oxidized to form an oxo or thio group. Cycloalkyl groups also include cycloalkylene groups. In some embodiments, the cycloalkyl group contains 0, 1, or 2 double bonds. In some embodiments, the cycloalkyl group contains 1 or 2 double bonds (partially unsaturated cycloalkyl groups). In some embodiments, the cycloalkyl group may be fused with an aryl group, a heteroaryl group, a cycloalkyl group, and a heterocycloalkyl group. In some embodiments, the cycloalkyl group may be fused with an aryl group, a cycloalkyl group, and a heterocycloalkyl group. In some embodiments, cycloalkyl groups can be fused with aryl groups and heterocycloalkyl groups. In some embodiments, cycloalkyl groups can be fused with aryl groups and cycloalkyl groups. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcaryl, bicyclo[1.1.1]pentanyl, bicyclo[2.1.1]hexanyl, and the like.
[0072] Unless otherwise specified, "cycloalkylene" refers to a divalent cycloalkyl group as defined above.
[0073] Unless otherwise specified, "alkoxy" refers to an alkyl group bonded to the rest of the molecule through an ether oxygen atom. Representative alkoxy groups are those having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and tert-butoxy. As used herein, "alkoxy" includes unsubstituted and substituted alkoxy groups, especially those substituted with one or more halogens. Preferred alkoxy groups are selected from OCH3, OCF3, CHF2O, CF3CH2O, i- PrO, n- PrO, i- BuO, n- BuO or t- BuO.
[0074] Unless otherwise specified, "aryl" refers to a hydrocarbon aromatic group. Aryl is monocyclic or polycyclic, for example, a monocyclic aryl ring fused to one or more carbocyclic aromatic groups. Examples of aryl include, but are not limited to, phenyl, naphthyl, and phenanthrenyl.
[0075] Unless otherwise specified, "aryloxy" refers to an aryl group bonded to the rest of the molecule through an ethereal oxygen atom. Examples of aryloxy groups include, but are not limited to, phenoxy and naphthoxy.
[0076] Unless otherwise specified, "arylene" refers to a divalent aromatic radical as defined above. Examples of arylene groups include, but are not limited to, 1,4-phenylene, 1,3-phenylene, 1,2-phenylene, naphthylene, and phenanthrenylene.
[0077] Unless otherwise specified, "heteroaryl" refers to a substituted or unsubstituted aromatic group containing one or more heteroatoms, the heteroatoms being independently selected from O, N or S, preferably 1, 2, 3 or 4 heteroatoms, preferably a 5-14 membered aromatic group containing 1-4 heteroatoms selected from oxygen, sulfur and nitrogen, more preferably a 5-9 membered aromatic group containing 1-2 heteroatoms selected from oxygen, sulfur or nitrogen, more preferably a 5-6 membered aromatic group containing 1-3 heteroatoms selected from oxygen, sulfur or nitrogen. The heteroaryl group is monocyclic or polycyclic. The monocyclic heteroaryl group is preferably a 5-6 membered aromatic group containing 1-3 heteroatoms selected from oxygen, nitrogen or sulfur. More preferably, it is a 5-6 membered aromatic group containing 1-2 heteroatoms selected from oxygen, nitrogen or sulfur. More preferably, it is a 5-6 membered aromatic group containing 1 heteroatom selected from oxygen, nitrogen or sulfur. In some embodiments, the monocyclic heteroaryl ring is fused with one or more carbocyclic aromatic groups or other monocyclic heterocycloalkyl groups. Examples of heteroaryl groups include, but are not limited to, pyridyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl, isoquinolyl, quinazolinyl, furanyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, isothiazolyl, pyrrolyl, indolyl, benzimidazolyl, benzofuranyl, benzothiazolyl, benzothienyl, benzoxazolyl, benzopyridinyl, pyrrolopyrimidinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, 1H-pyrrolo[3,2-c]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl,
[0078] Unless otherwise specified, "heteroarylene" refers to a divalent heteroaryl group as defined above.
[0079] Unless otherwise specified, "heterocycloalkyl" refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene groups as part of the ring structure, having at least one heteroatom ring member independently selected from boron, phosphorus, nitrogen, sulfur, oxygen, and selenium, preferably a saturated or partially unsaturated ring containing 1-4 heteroatoms selected from oxygen, sulfur, or nitrogen, more preferably a saturated or partially unsaturated ring containing 1-2 heteroatoms selected from oxygen, sulfur, or nitrogen. In some embodiments, heterocycloalkyl is a 5-14 membered non-aromatic ring containing ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, or sulfur (5-14 membered heterocycloalkyl). In some embodiments, heterocycloalkyl is a 3-9 membered non-aromatic ring containing ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, or sulfur (3-9 membered heterocycloalkyl). In some embodiments, heterocycloalkyl is a 5-8 membered non-aromatic ring containing ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, or sulfur (5-8 membered heterocycloalkyl). In some embodiments, heterocycloalkyl is a 5-6 membered non-aromatic ring containing ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, or sulfur (5-6 membered heterocycloalkyl). In some embodiments, 5-6 membered heterocycloalkyl contains 1-3 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, 5-6 membered heterocycloalkyl contains 1-2 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, 5-6 membered heterocycloalkyl contains 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. In some embodiments, heterocycloalkyl is a 10-13 membered non-aromatic ring containing ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, or sulfur (10-13 membered heterocycloalkyl). In some embodiments, 10-13 membered heterocycloalkyl groups contain 1-3 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, 10-13 membered heterocycloalkyl groups contain 1-2 ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, 10-13 membered heterocycloalkyl groups contain 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. If the heterocycloalkyl group contains at least one double bond, the partially unsaturated heterocycloalkyl group may be referred to as a "heterocycloalkenyl group," or if the heterocycloalkyl group contains at least one triple bond, the partially unsaturated heterocycloalkyl group may be referred to as a "heterocycloalkynyl group." Heterocycloalkyl groups may include monocyclic, bicyclic, spirocyclic, or polycyclic (e.g., having two fused or bridged rings) ring systems. In some embodiments, heterocycloalkyl groups are monocyclic groups having 1, 2, or 3 heteroatoms independently selected from nitrogen, sulfur, and oxygen. The ring-forming carbon atoms and heteroatoms of the heterocycloalkyl group may be optionally oxidized to form oxo or thio or other oxidized bonds (e.g., C(O), S(O), C(S) or S(O) 2, N-oxide, etc.), or the nitrogen atom may be quaternized. The heterocycloalkyl group may be connected via ring-forming carbon atoms or ring-forming heteroatoms. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds.In some embodiments, heterocycloalkyl contains 0 to 2 double bonds. Also included in the definition of heterocycloalkyl are moieties (also referred to as partially unsaturated heterocycles) with one or more aromatic rings fused to the heterocycloalkyl ring (i.e., sharing a key therewith), such as benzo derivatives of piperidine, morpholine, azacycloheptane or tetrahydrothienyl, and pyrido derivatives of piperidine, morpholine, azacycloheptane or tetrahydrothienyl. Heterocycloalkyl containing fused aromatic rings can be connected via any ring-forming atoms, including ring-forming atoms of the fused aromatic ring. Examples of heterocycloalkyl groups include, but are not limited to, azetidinyl, azepanyl, dihydrobenzofuranyl, dihydrofuranyl, dihydropyranyl, N-morpholinyl, 3-oxa-9-azaspiro[5.5]undecyl, 1-oxa-8-azaspiro[4.5]decyl, piperidinyl, piperazinyl, oxopiperazinyl, pyranyl, pyrrolidinyl, quinuclyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydroquinolinyl, tropanediyl, 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridinyl, 4,5,6,7-tetrahydro-1H-imidazole , 4-nitro-2-nitro-1-pyridine, 4 ...1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine, 4-nitro-1-pyridine,
[0080] Unless otherwise specified, "heterocycloalkylene" refers to a divalent heterocycloalkyl group as defined above.
[0081] Unless otherwise specified, "heterocyclic spiroalkyl" refers to a polycyclic hydrocarbon group formed by two or more saturated or partially unsaturated monocyclic rings sharing a carbon atom (called a spiro atom), wherein one or more (such as 1, 2 or 3) ring atoms are selected from nitrogen, oxygen or S(O) p(wherein p is 0, 1 or 2) heteroatom, and the remaining ring atoms are carbon. When the heteroatom is a nitrogen atom, the nitrogen atom can be substituted or unsubstituted (i.e. N or NR, R is hydrogen or other substituents defined herein). Each monocycle can contain one or more double bonds, but no ring has a completely conjugated π electron system. Spiro heterocyclic groups are divided into single spiro heterocyclic groups, double spiro heterocyclic groups or multi-spiro heterocyclic groups according to the number of shared spiro atoms between the rings. The term "(5-15 yuan) heterocyclic spiroalkyl" refers to a heterocyclic spiroalkyl group with 5 to 15 ring atoms, wherein the monocycle with shared spiro atoms is a 3 to 8-membered monocycle, and at least one monocycle is a heterocyclic alkyl ring. Preferably, it is a (6-18 yuan) heterocyclic spiroalkyl group with 6 to 18 ring atoms, wherein 1-3 ring atoms are heteroatomic, more preferably a (7-15 yuan) heterocyclic spiroalkyl group with 7 to 15 ring atoms, wherein 1-3 ring atoms are heteroatomic. Most preferably, it is a 9-membered (4-membered monocyclic (heterocyclic) base ring / 6-membered monocyclic (heterocyclic) base ring, a 5-membered monocyclic (heterocyclic) base ring / 5-membered monocyclic (heterocyclic) base ring), a 10-membered (5-membered monocyclic (heterocyclic) base ring / 6-membered monocyclic (heterocyclic) base ring) or an 11-membered (6-membered monocyclic (heterocyclic) base ring / 6-membered monocyclic (heterocyclic) base ring) monospiro heterocyclic group. Specific examples of heterocyclic spiroalkyl groups include, but are not limited to
[0082] Unless otherwise specified, "oxo" refers to =0; for example, a carbonyl group substituted with an oxo group is a "carbonyl group." "; the group formed by sulfur being replaced by an oxo group is called "sulfinyl" ", the group formed by sulfur being substituted by two oxo groups is called "sulfonyl" ”.
[0083] Unless otherwise specified, "halogen" (or halo) refers to fluorine, chlorine, bromine or iodine. The term "halo" (or "halogen substituted") appearing before the name of a group indicates that the group is partially or fully halogenated, that is, substituted by F, Cl, Br or I in any combination, preferably substituted by F or Cl.
[0084] Unless otherwise specified, the term "substituted" refers to a substituent group other than one or more hydrogen atoms on a specified atom or group that is substituted by one or more hydrogen atoms, without exceeding the normal valence of the specified atom. For example, one or more hydrogen atoms of an alkyl, alkylene, alkenyl, alkynyl, hydroxyl or amido group can be substituted by one or more substituent groups. Wherein the substituent group includes but is not limited to alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxylate, cyano, guanidino, halogen, haloalkyl, heteroalkyl, heteroaryl, heterocyclic radical, hydroxyl, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, mercaptan, thioketone or its combination. The definition of "substituted" does not include similar indefinite structures obtained by defining a substituent group having a further substituent group attached to infinity (for example, a substituted aryl group itself substituted by a substituted aryl group with a substituted alkyl group, which is further substituted by a substituted heteroalkyl group, etc.). Unless otherwise specified, the maximum number of consecutive substitutions in the compounds described herein is three. For example, a substituted aryl group is continuously substituted by two other substituted aryls to an aryl group substituted by ((substituted aryl) substituted aryl). Similarly, the above definition does not include substitution patterns that are not allowed (for example, a methyl group substituted by 5 fluorines or a heteroaryl group with two adjacent oxygen ring atoms). This substitution pattern that is not allowed is well known to those skilled in the art. Whenever used to modify a chemical group, "substituted" can describe other chemical groups defined herein. For example, the term "substituted aryl" includes but is not limited to "alkyl aryl". Unless otherwise specified, if a group is described as optionally substituted, any substituent of the group itself is unsubstituted.
[0085] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0086] Unless otherwise specified, "acyl" refers to -C(=O)-R, where R is selected from optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, or heterocycloalkyl.
[0087] Unless otherwise specified, it will be understood that the word "comprise", or variations such as "comprises" or "comprising", imply the inclusion of a stated element or integer, or group of elements or integers, but not the exclusion of any other element or integer, or group of elements or integers.
[0088] The substituent "-O-CH2-O-" refers to the substituent in which two oxygen atoms are connected to two adjacent carbon atoms of a heterocycloalkyl, aryl or heteroaryl group, for example:
[0089] When the number of a linking group is 0, such as -(CH2)0-, it means that the linking group is a single bond.
[0090] When one of the variables is selected from a chemical bond, it means that the two groups it connects are directly connected. For example, when L in XLY represents a chemical bond, it means that the structure is actually XY.
[0091] The term "membered ring" includes any cyclic structure. The term "membered" refers to the number of atoms that make up the ring. For example, cyclohexyl, pyridyl, pyranyl, and thiopyranyl are six-membered rings, while cyclopentyl, pyrrolyl, furanyl, and thiophenyl are five-membered rings.
[0092] The term "fragment" refers to a specific part or functional group of a molecule. A chemical fragment is generally considered to be a chemical entity contained in or attached to a molecule.
[0093] The term "isomer" means any tautomer, stereoisomer, isotope, enantiomer or diastereomer of any compound of the present invention. The compounds of the present invention may have one or more chiral centers or double bonds and are therefore present in stereoisomeric form, for example, in double bond isomers (i.e., E / Z geometric isomers) or diastereomers (e.g., enantiomers (i.e., (+) or (-)) or cis / trans isomers). Therefore, the compounds of the present invention encompass all corresponding stereoisomers, i.e., stereoisomerically pure (e.g., geometrically pure, enantiomerically pure or diastereomerically pure) forms as well as enantiomers and stereoisomer mixtures, such as racemates. Enantiomeric and stereoisomeric mixtures of the compounds of the present invention can be separated into their component enantiomers or stereoisomers by well-known methods, such as chiral gas chromatography, chiral high performance liquid chromatography, and crystallization of the compounds as chiral salt complexes or crystallization of the compounds in chiral solvents. Enantiomers and stereoisomers can also be obtained from stereoisomerically pure or enantiomerically pure intermediates, reagents and catalysts by well-known asymmetric synthetic methods.
[0094] The term "isotopomers" refers to different molecules whose structures differ only in one isotope but are otherwise identical.
[0095] Specific pharmaceutical and medical terms
[0096] The term "acceptable," as used herein, means that a prescribed ingredient or active ingredient has no undue adverse effect on health and well-being for the general purpose of treatment.
[0097] The terms "treat," "treatment," or "therapy" as used herein include alleviating, inhibiting, or ameliorating the symptoms of a disease or condition; inhibiting the development of complications; ameliorating or preventing underlying metabolic syndrome; inhibiting the development of a disease or symptom, such as controlling the progression of a disease or condition; alleviating a disease or symptom; causing a regression of a disease or symptom; alleviating complications caused by a disease or symptom, or preventing or treating signs caused by a disease or symptom. As used herein, a compound or pharmaceutical composition, upon administration, can improve a disease, symptom, or condition, particularly by improving its severity, delaying its onset, slowing its progression, or reducing its duration. Whether the administration is fixed or temporary, continuous or intermittent, the circumstances attributable to or related to the administration can be explained.
[0098] "Active ingredient" refers to the compound of formula (1), as well as pharmaceutically acceptable inorganic or organic salts of the compound of formula (1). The compounds of the present invention may contain one or more asymmetric centers (chiral centers or axial chirality) and therefore appear in the form of racemates, racemic mixtures, single enantiomers, diastereomeric compounds and single diastereomers. The asymmetric centers that may exist depend on the properties of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers, and all possible optical isomers and diastereomeric mixtures as well as pure or partially pure compounds are included within the scope of the present invention. The present invention is meant to include all such isomeric forms of these compounds.
[0099] The terms "compound," "composition," "agent," or "medicine or medicament" are used interchangeably herein and refer to a compound or composition that, when administered to a subject (human or animal), induces a desired pharmaceutical and / or physiological response through local and / or systemic action.
[0100] The term "administered," "administering," or "administration" as used herein refers to the direct administration of the compound or composition, or the administration of a prodrug, derivative, or analog of the active compound.
[0101] Although the numerical ranges and parameters used to define the broader scope of the present invention are approximate, the numerical values of the specific examples are presented herein as precisely as possible. However, any numerical value inherently and inevitably contains standard deviations resulting from individual testing methods. As used herein, "about" generally refers to the actual value being within plus or minus 10%, 5%, 1%, or 0.5% of a particular value or range. Alternatively, the term "about" means that the actual value falls within an acceptable standard error of the mean, as determined by one skilled in the art. Except in the experimental examples, or unless otherwise expressly indicated, all ranges, amounts, values, and percentages used herein (e.g., to describe material amounts, time periods, temperatures, operating conditions, quantitative ratios, and the like) are to be understood as modified by the word "about." Therefore, unless otherwise indicated, the numerical parameters disclosed in this specification and the appended claims are approximate and may be modified as needed. At a minimum, these numerical parameters should be understood to include the number of significant digits indicated and to include normal rounding.
[0102] Unless otherwise defined in this specification, the scientific and technical terms used herein have the same meanings as commonly understood by those skilled in the art. In addition, unless otherwise defined in this specification, singular terms used in this specification include the plural form of the term, and plural terms also include the singular form of the term, unless otherwise defined in the context.
[0103] Therapeutic uses
[0104] The present invention provides methods for treating diseases using the compounds of formula (1) or pharmaceutical compositions of the present invention, including but not limited to conditions involving HDAC (eg, cancer).
[0105] In some embodiments, a method for treating cancer is provided, comprising administering to a subject in need thereof an effective amount of any of the aforementioned pharmaceutical compositions comprising a compound of formula (1). In some embodiments, the cancer is mediated by HDAC enzymes. In some embodiments, the compounds of the present invention are used in combination with an immune checkpoint inhibitor; in some embodiments, the compounds of the present invention are used in combination with a PD-1 or PD-L1 inhibitor; in some embodiments, the compounds of the present invention are used in combination with a PD-1 antibody; in some embodiments, the compounds of the present invention are used in combination with a PD-L1 antibody; in some embodiments, the compounds of the present invention are used in combination with a VEGF / VEGFR inhibitor; in some embodiments, the compounds of the present invention are used in combination with an immune checkpoint inhibitor and a VEGF / VEGFR inhibitor; in some embodiments, the compounds of the present invention are used in combination with a PD-1 inhibitor and a VEGF / VEGFR inhibitor; in some embodiments, the compounds of the present invention are used in combination with a PD-1 antibody and a VEGF / VEGFR inhibitor; wherein the PD-1 antibody includes but is not limited to nivolumab, pembrolizumab, toripalimab, sintilimab, camrelizumab, tislelizumab, penampalimab, sepalimab, slulizumab, putalimab, pidilizumab, cemiprilimab, spartalizumab, AMG404 , RN888, mAb15, MEDI-0680, BGB-108, spartalizumab, IBI-308, mDX-400, SHR-1210, PF-06801591, PDR-001, GB-226 and STI-1110, as well as biosimilars, bioenhancers and bioequivalents of these inhibitors; wherein the PD-L1 antibodies include but are not limited to durvalumab, atezolizumab, envomalimab, sugemalimab, velumab, evolozumab, BMS-93 6559, AMP-714, ALN-PDL, TSR-042, KD-033, CA-170, STI-1014 and KY-1003, as well as biosimilars, bioenhancers and bioequivalents of these inhibitors; wherein the VEGF / VEGFR inhibitors include but are not limited to bevacizumab, ranibizumab, ramucirumab, sorafenib, axitinib, apatinib, sunitinib, regorafenib, vandetanib, pazopanib, lenvatinib, cabozantinib, ponatinib, aflibercept and fruquintinib. In other embodiments, the tumor range includes but is not limited to breast cancer, colon cancer, uterine cancer, pancreatic cancer, lung cancer, gastric cancer, blood cancer, lymphoma, prostate cancer, liver cancer, cervical cancer, neuroblastoma, melanoma or intracranial tumor.
[0106] Route of administration
[0107] The compounds of the present invention and their pharmaceutically acceptable salts can be formulated into various formulations containing a safe and effective amount of the compounds of the present invention or their pharmaceutically acceptable salts and a pharmacologically acceptable excipient or carrier. "Safe and effective amount" means an amount of the compound sufficient to significantly improve the condition without causing serious side effects. The safe and effective amount of the compound will be determined based on the patient's age, condition, and duration of treatment, among other factors.
[0108] "Pharmaceutically acceptable excipients or carriers" refer to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmacologically acceptable excipients or carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0109] The compounds of the present invention may be administered orally, rectally, parenterally (intravenously, intramuscularly or subcutaneously), or topically.
[0110] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
[0111] Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifying agents, and the release of the active compound or compounds in such compositions can be delayed in a certain portion of the digestive tract. Examples of useful encapsulating components are polymeric substances and waxes. If desired, the active compound can also be microencapsulated with one or more of the above-mentioned excipients.
[0112] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, or mixtures thereof.
[0113] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0114] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances.
[0115] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0116] Dosage forms for topical administration of the compounds of this invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.
[0117] The compounds of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds. When using a pharmaceutical composition, a safe and effective amount of the compounds of the present invention is applied to a mammal (e.g., a human) in need of treatment, wherein the dosage is a pharmaceutically effective dosage. For a 60 kg human, the daily dosage is generally 1 to 2000 mg, preferably 50 to 1000 mg. Of course, the specific dosage should also take into account factors such as the route of administration and the patient's health status, all of which are within the skill of a skilled physician.
[0118] The features described above, or in the embodiments, may be combined in any combination. All features disclosed in this specification may be used in any combination, and each feature disclosed in this specification may be replaced by any alternative feature that serves the same, equivalent, or similar purpose. Therefore, unless otherwise specified, the features disclosed are merely general examples of equivalent or similar features. DETAILED DESCRIPTION
[0119] The following description will elaborate on various specific aspects, characteristics, and advantages of the above-mentioned compounds, methods, and pharmaceutical compositions so that the present invention will be readily apparent. It should be understood that the following detailed description and examples describe specific embodiments and are provided for reference only. After reading the present description, those skilled in the art may make various changes or modifications to the present invention, and such equivalents are within the scope of the present invention.
[0120] In all embodiments, 1 H-NMR was recorded on a Varian Mercury 400 nuclear magnetic resonance instrument, and chemical shifts are expressed in δ (ppm). Silica gel used for separation was 200-300 mesh unless otherwise specified, and the eluent ratios were all by volume.
[0121] The present invention uses the following abbreviations: AcOH represents glacial acetic acid; Boc2O represents di-tert-butyl dicarbonate; CDCl3 represents deuterated chloroform; CD3I represents deuterated iodomethane; Cs2CO3 represents cesium carbonate; DCM represents dichloromethane; DCE represents 1,2-dichloroethane; Diox represents 1,4-dioxane; DIPEA represents diisopropylethylamine; DMSO represents dimethylsulfoxide; DMAP represents 4-dimethylaminopyridine; DMF represents N,N-dimethylformamide; EA represents ethyl acetate; EtOH represents anhydrous ethanol; Flash represents fast medium pressure preparative chromatography; h represents hour; H2 represents hydrogen; HATU represents 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate; HCl represents hydrochloric acid; K2C O3 represents anhydrous potassium carbonate; K3PO4 represents anhydrous potassium phosphate; LC-MS represents liquid chromatography-mass spectrometry; LiOH represents lithium hydroxide; LiOH.H2O represents lithium hydroxide monohydrate; MeOH represents anhydrous methanol; min represents minute; mL represents milliliter; LC-MS represents mass spectrometry; NaBH(OAc)3 represents sodium triacetoxyborohydride; NMR represents nuclear magnetic resonance; NH4OAc represents ammonium acetate; Pd / C represents palladium on carbon; Pd(dppf)2Cl2 represents [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex; Pd(OAc)2 represents palladium acetate; TFA represents trifluoroacetic acid; THF represents tetrahydrofuran; Xantphos represents 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; and Zn represents zinc powder.
[0122] Preparation Example 1 Synthesis of 4-((dimethylsulfinylamino)benzoic acid (S1-1)
[0123] Synthesis of S1-1a:
[0124] To a 1-L single-necked flask, methyl 4-bromobenzoate (21.5 g, 100.0 mmol), Xantphos (5.78 g, 10 mmol), Cs2CO3 (81.5 g, 250.0 mmol), Diox (500 mL), and dimethylsulfenyl imide (10.23 g, 110.0 mmol) were added. After purging the mixture with argon, Pd(OAc)2 (1.13 g, 5.0 mmol) was added. The mixture was heated to 100°C under argon and stirred for 8 h. After completion of the reaction, as determined by LC-MS, the mixture was cooled, filtered, and the filter cake was rinsed with EA (~100 mL). The filtrate was concentrated, and the residue was added with water (200 mL) and EA (200 mL), stirred, and separated. The organic phase was washed with saturated sodium chloride solution and concentrated. The residue was purified by column chromatography to afford the product as a light brown oil (19.3 g, yield: 85%).
[0125] ESI-MS m / z:228.1[M+H] + .
[0126] Synthesis of S1-1:
[0127] To a 1L single-necked flask, compound S1-1a (19.3 g, 85.02 mmol), THF (300 mL), MeOH (100 mL), water (100 mL), and lithium hydroxide monohydrate (14.28 g, 340.0 mmol) were added. The mixture was stirred at room temperature for 20 h. After completion of the reaction, the mixture was concentrated to approximately one-third of the remaining volume, and the pH was adjusted to 2-3 with 2N HCl. The mixture was extracted twice with EA (200 mL x 2). The combined organic phases were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated to afford an off-white solid (15.2 g, 83.9% yield).
[0128] ESI-MS m / z:214.1[M+H] + .
[0129] Preparation Example 2 4-((4-methyl-1-oxo-1 λ Synthesis of 6-thiomorpholin-1-imino)amino)benzoic acid (S1-2)
[0130] Synthesis of S1-2a:
[0131] To a 100 mL single-necked flask, N-Boc-thiomorpholine (1 g, 4.22 mmol), EtOH (20 mL), ammonium acetate (1.3 g, 16.88 mmol), and iodophenyldiacetic acid (4.07 g, 12.66 mmol) were added. The mixture was purged with argon and stirred at room temperature for 20 h. After completion of the reaction by LC-MS, the mixture was concentrated. Water (50 mL) and EA (50 mL) were added to the residue, stirred, and the layers separated. The organic phase was washed with saturated sodium chloride solution and concentrated. The residue was purified by column chromatography to afford the product as a light brown oil (925 mg, yield: 81.8%).
[0132] ESI-MS m / z:269.1[M+H] + .
[0133] Synthesis of S1-2b:
[0134] To a 1-L single-necked flask, methyl 4-bromobenzoate (741 mg, 3.45 mmol), Xantphos (279 mg, 0.5 mmol), Cs2CO3 (2.81 g, 8.62 mmol), Diox (20 mL), and S1-2a (925 mg, 3.45 mmol) were added. After purging the mixture with argon, Pd(OAc)2 (113 mg, 0.5 mmol) was added. The mixture was heated to 100°C and stirred for 4 h under argon. After completion of the reaction, LC-MS analysis confirmed the reaction was complete. The mixture was cooled, filtered, and the filter cake was rinsed with EA (~20 mL). The filtrate was concentrated. The residue was added with water (30 mL) and EA (30 mL), stirred, and separated. The organic phase was washed with saturated sodium chloride solution and concentrated. The residue was purified by column chromatography to afford the product as a light brown oil (1.05 g, yield: 75.6%).
[0135] ESI-MS m / z:403.1[M+H] + .
[0136] Synthesis of S1-2c:
[0137] To a 250 mL single-necked flask was added compound S1-2b (900 mg, 2.24 mmol), MeOH (10 mL), and 10% Pd / C (100 mg). The mixture was replaced with hydrogen three times and stirred at room temperature and atmospheric pressure for 20 h. After completion of the reaction as determined by LC-MS, the mixture was filtered through celite, and the filtrate was concentrated to dryness to afford an off-white solid (624 mg, 100% yield).
[0138] ESI-MS m / z:269.1[M+H] + .
[0139] Synthesis of S1-2d:
[0140] To a 50 mL single-necked flask, the above-mentioned compound S1-2c (104 mg, crude product, 0.373 mmol), DCE (5 mL), AcOH (30 mg, 0.5 mmol), and paraformaldehyde (16 mg, 0.533 mmol) were added. The mixture was stirred at room temperature for 30 min, and then NaBH(OAc)3 (158 mg, 0.746 mmol) was added. The mixture was stirred at room temperature for 20 h. After the reaction was completed as determined by LC-MS, DCM (10 mL) and water (10 mL) were added to the system, stirred, separated, and the aqueous phase was extracted with DCM (10 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product.
[0141] ESI-MS m / z:283.1[M+H] + .
[0142] Synthesis of S1-2:
[0143] To a 50 mL single-necked vial was added compound S1-2d (126 mg, crude product, 0.373 mmol), THF (5 mL), MeOH (2 mL), water (2 mL), and lithium hydroxide monohydrate (155 mg, 3.7 mmol). The mixture was stirred at room temperature for 2 h. After completion of the reaction, as determined by LC-MS, the mixture was concentrated, the residue flash purified, and lyophilized to afford an off-white solid (76 mg, 75.9% yield).
[0144] ESI-MS m / z:269.1[M+H] + .
[0145] Preparation Example 3 4-((4-methyl-d3-1-oxo-1 λ Synthesis of 6-thiomorpholin-1-imino)amino)benzoic acid (S1-3)
[0146] Synthesis of S1-3a:
[0147] To a 25 mL single-necked flask, compound S1-2c (104 mg, crude product, 0.373 mmol), DMF (5 mL), K2CO3 (155 mg, 1.12 mmol), and CD3I (60 mg, 0.448 mmol) were added. The mixture was stirred at room temperature for 2 h. After completion of the reaction as determined by LC-MS, EA (10 mL) and water (10 mL) were added, stirred, and separated. The aqueous phase was extracted with EA (10 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to yield 156 mg of the crude product.
[0148] ESI-MS m / z:286.1[M+H] + .
[0149] Synthesis of S1-3:
[0150] To a 25 mL single-necked vial was added compound S1-3a (156 mg, crude product, 0.373 mmol), THF (5 mL), MeOH (2 mL), water (2 mL), and lithium hydroxide monohydrate (155 mg, 3.7 mmol). The mixture was stirred at room temperature for 2 h. After completion of the reaction, as determined by LC-MS, the mixture was concentrated, the residue flash purified, and lyophilized to afford the product as an off-white solid (57 mg, 56.3% yield).
[0151] ESI-MS m / z:272.1[M+H] + .
[0152] Using different raw materials, the target intermediates S1-4 to S1-23 in Table 1 were obtained by the synthesis method of intermediates S1-1, S1-2 and S1-3.
[0153] Table 1. Structural formulas of intermediates S1-4 to S1-23
[0154] Example 1 N-(4-amino-4'-fluoro-[1,1'-biphenyl]-3-yl)-4-((dimethyl(oxo)-1 λ Synthesis of 6-thio)amino)benzamide (Compound 1)
[0155] Step 1: Synthesis of compound 1-1:
[0156] To a 500 mL single-necked flask, tert-butyl (2-amino-4-bromophenyl)carbamate (5.0 g, 17.42 mmol), DIPEA (3.37 g, 26.13 mmol), S1-1 (3.71 g, 17.42 mmol), HATU (9.92 g, 26.13 mmol), and DMF (100 mL) were added. The mixture was purged with argon and stirred at room temperature for 20 h. After completion of the reaction, as determined by LC-MS, the mixture was quenched with water (200 mL) and extracted twice with EA (100 mL x 2). The combined organic phases were washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography to afford the product as a white solid (7.22 g, yield: 86.0%).
[0157] ESI-MS m / z:482.1[M+H] + .
[0158] Step 2: Synthesis of compound 1-2:
[0159] To a 100 mL single-necked flask, compound 1-1 (100 mg, 0.207 mmol), K₃PO₄ (110 mg, 0.52 mmol), Diox / H₂O (5 mL / 1 mL), 4-fluorophenylboronic acid (35 mg, 0.25 mmol), and Pd(dppf)₂Cl₂ (14 mg) were added. The mixture was purged with argon and heated to 100°C with stirring for 2 h. After completion of the reaction, the mixture was concentrated by LC-MS. The residue was flash purified to afford the product as a light brown oil (56 mg, 54.4% yield).
[0160] ESI-MS m / z:498.2[M+H] + .
[0161] Step 3: Synthesis of compound 1:
[0162] To a 25 mL single-necked vial was added compound 1-2 (56 mg, 0.113 mmol), DCM (5 mL), and TFA (0.5 mL). The mixture was stirred at room temperature for 2 h. After completion of the reaction, as determined by LC-MS, the system was concentrated, the residue flash purified, and lyophilized to afford the product as an off-white solid (33 mg, 73.5% yield).
[0163] ESI-MS m / z:398.1[M+H] + .
[0164] Similar to the synthesis of compound 1, target compound 2-139 in Table 2 can be obtained by using different intermediates as raw materials.
[0165] Table 2
[0166] The NMR data of some compounds in this patent are listed in Table 3 below:
[0167] Table 3
[0168] Biological Example 1 Inhibitory activity test of the compounds of the present invention on HDAC enzyme subtypes
[0169] The compound of the present invention uses the FRET method to determine the enzyme inhibitory activity on each subtype of HDAC enzyme. Each subtype of HDAC enzyme is obtained by purification or direct purchase of a kit.
[0170] Specific method: Add enzyme to a 384-well plate and add reaction buffer to the control wells. Add gradient diluted DMSO sample solution to the reaction wells, incubate at room temperature for 15 minutes, then add color developer to terminate the reaction and generate fluorescence. Use EnVision multi-label microplate reader to detect fluorescence intensity (excitation light: 355nM, emission light: 460nM). Read the terminal value after the color development reaches stability. Use GraphPad Prism4 software to calculate the compound inhibition IC compared with DMSO. 50 .
[0171] Table 4 Inhibitory activity of the compounds of the present invention on HDAC1, 2, 3 enzymes (IC 50 ,nM) A stands for IC 50 ≤500nM; B indicates 500nM <IC 50 ≤5uM; C represents IC 50 >5uM.
[0172] Table 5 Inhibitory activity of the compounds of the present invention on HDAC1, 2, 3 enzymes (IC 50 ,nM) ++++ indicates IC 50 ≤30nM; +++ means 30nM <IC 50 ≤300nM; ++ means 300nM <IC 50 ≤3uM; + indicates IC 50 >3uM.
[0173] Table 6 Inhibitory activity of the compounds of the present invention on HDAC isoforms (IC 50 ,nM)
[0174] Note: The reference compound is N-(4-amino-4'-fluoro-[1,1'-biphenyl]-3-yl)-4-(S-methylsulfonylimino)benzamide; ND means not detected.
[0175] Biological Example 2 Inhibitory test of Jurkat and 293T cell proliferation by the compounds of the present invention
[0176] 3000 Jurkat or 293T cells were seeded in a 96-well plate. After overnight adherence, serial dilutions of the compound were added. After 72 hours, intracellular ATP levels were measured using CTG. The IC value of the compound for inhibiting cell proliferation was calculated compared to DMSO. 50 .
[0177] Table 7 Inhibitory activity of the compounds of the present invention on Jukat / 293T cell proliferation (IC 50 ,nM)
[0178] Biological Example 3 Determination of the Effect of the Compounds of the Present Invention on the Level of Acetyl Lysine / H3K 27 in Cells
[0179] 20,000 HeLa cells were seeded per well in a 96-well plate. After overnight attachment, serially diluted compounds were added. After 24 hours of treatment, the levels of intracellular acetyl lysine and H3K 27 acetyl lysine were detected by ELISA.
[0180] Table 8 Effects of the compounds of the present invention on the levels of acetyl lysine and H3K 27
[0181] Biological Example 4 Metabolic Kinetics Experiment of the Compounds of the Present Invention in Mice
[0182] Female CD-1 mice aged 7 to 10 weeks were administered intravenously and orally at doses of 1 mg / kg and 10 mg / kg, respectively. Mice were fasted for at least 12 hours before dosing and resumed feeding 4 hours after dosing. Water was available ad libitum throughout the experiment.
[0183] On the day of the experiment, animals in the intravenous group received a single injection of the corresponding compound via the tail vein at a volume of 10 mL / kg; animals in the oral group received a single injection of the corresponding compound via gavage at a volume of 10 mL / kg. Animals were weighed before dosing, and the dosing volume was calculated based on body weight. Samples were collected at 0.083, 0.167, 0.5, 1, 2, 4, 8, and 24 h. Approximately 200 μL of whole blood was collected via the orbital venous plexus at each time point and used to prepare plasma for concentration determination by high-performance liquid chromatography-tandem mass spectrometry (LC-MS / MS). Plasma concentrations were analyzed using a non-compartmental model using Winnolin pharmacokinetic software, and pharmacokinetic parameters were calculated using the linear-log trapezoidal method.
[0184] Table 9 In vivo pharmacokinetic evaluation results of the compounds of the present invention
[0185] Biological Example 5 Liver microsomal stability test of the compound of the present invention
[0186] 1 μM compound was incubated with 500 mg / mL human, monkey, beagle, rat or mouse liver microsomes and NADPH regeneration system at 37°C for different time periods. The remaining amount of compound was analyzed by LC-MS-MS and T was calculated. 1 / 2 .
[0187] Table 10 Evaluation results of the stability of the compounds of the present invention in human and mouse liver microsomes
[0188] As can be seen from the results in the above table, the compounds of the present invention are more stable in human liver microsomes than the control compounds.
[0189] Biological Example 6 In vivo efficacy experiment of the compound of the present invention in MC-38 model
[0190] Female C57BL6N mice (6 weeks, 18-22 g) were provided by Weitong Lihua Co., Ltd., China, and used after one week of quarantine and acclimatization. All animals were housed in a room at 23 ± 2°C, 50 ± 5% relative humidity, with artificial lighting from 08:00 to 20:00 daily and 13-18 air changes per hour. They had free access to a standard laboratory diet and water.
[0191] Mouse colon cancer MC38 cells were routinely cultured in 1640 medium containing 10% fetal bovine serum at 37°C in a 5% CO2 incubator. After passage, the cells were collected when the cells reached the required number. 2×10 6 MC38 cells were used to form tumors, and the tumors were grown to 100 mm. 3 After approximately 14 days, the animals were randomly divided into groups and dosing began. Tumor volumes were measured with calipers on days 3, 7, 10, 14, 17, 21, and 28 after dosing. The ability of the compounds to inhibit tumor growth was evaluated using the formula: tumor growth inhibition (TGI) = 1 - (tumor volume of the dosing group on day 28 - tumor volume of the dosing group on day 1) / (tumor volume of the control group on day 28 - tumor volume of the control group on day 1). The toxicity of the compounds was assessed based on the weight and condition of the mice.
[0192] The groups are as follows:
[0193] 1) Solvent control group; 2) PD-1 + Reg group; 3) Compound 1; 4) Control compound group; 5) Compound 1 (10 mg / kg) and PD-1 + Reg group; 6) Compound 1 (30 mg / kg) and PD-1 + Reg group; 7) Compound 1 (90 mg / kg) and PD-1 + Reg group; 8) Control compound (10 mg / kg) and PD-1 + Reg group; 9) Control compound (30 mg / kg) and PD-1 + Reg group; 10) Control compound (90 mg / kg) and PD-1 + Reg group, with 6 mice in each group. The results are shown in Table 11 below.
[0194] Table 11 In vivo efficacy of some compounds of the present invention in MC-38 model
[0195] Note: Reg indicates regorafenib; PD-1 indicates anti-PD-1 antibody; IV indicates intravenous administration; PO indicates oral administration; QD indicates once-a-day administration; QW indicates once-a-week administration; CR indicates complete remission (complete disappearance of the tumor after the administration cycle); PR indicates partial remission (tumor volume decreases by more than 30% relative to the initial volume after the administration cycle); SD indicates stable disease (tumor volume decreases or increases by no more than 30% relative to the initial volume after the administration cycle); Died indicates mouse death; administration cycle * After 10 consecutive days of QD administration, all drugs were stopped for 16 days, and QW was only administered on the 1st and 8th days.
[0196] The in vivo experimental results above demonstrate that the compounds of the present invention, whether used alone or in combination with PD-1 and Reg, exhibit significant inhibitory effects on the MC-38 tumor model in vivo. Compound 1 alone completely regressed tumors in 83.3% (5 / 6) of mice, while the triple combination of Compound 1, PD-1, and Reg achieved complete tumor regression in 83.3% (5 / 6) of mice at a lower dose, and in 100% (5 / 5) of mice at a higher dose. Compared to the control compound, both single-agent and triple-combination treatments demonstrated significant tumor growth inhibition advantages at equivalent doses.
[0197] Biological Example 7 In vivo efficacy experiment of the compound of the present invention in CT-26 model
[0198] Female BALB / c mice (6 weeks, 18-22 g) were provided by Weitong Lihua Co., Ltd., China, and used after one week of quarantine and acclimatization. All animals were housed in a room at 23±2°C, 50±5% relative humidity, with artificial lighting from 08:00 to 20:00 daily and 13-18 air changes per hour.
[0199] Mouse colon cancer CT-26 cells were routinely cultured in 1640 medium containing 10% fetal bovine serum at 37°C in a 5% CO2 incubator. After passage, the cells were collected when the cells reached the required number. 2×10 5 CT-26 cells were used to form tumors, and the tumors were grown to 100 mm. 3 After approximately 14 days, the animals were randomly divided into groups and dosing began. Tumor volumes were measured with calipers on days 3, 7, 10, 14, 17, 21, and 28 after dosing. The ability of the compounds to inhibit tumor growth was evaluated using the formula: tumor growth inhibition (TGI) = 1 - (tumor volume of the dosing group on day 28 - tumor volume of the dosing group on day 1) / (tumor volume of the control group on day 28 - tumor volume of the control group on day 1). The toxicity of the compounds was assessed based on the weight and condition of the mice.
[0200] The groups are as follows:
[0201] 1) Solvent control group; 2) PD-1 + Reg group; 3) Compound 1-A (30 mg / kg); 4) Compound 1-B (90 mg / kg); 5) Control Compound-A (30 mg / kg); 6) Control Compound-B (90 mg / kg); 7) Compound 1 (10 mg / kg) and PD-1 + Reg group; 8) Compound 1 (30 mg / kg) and PD-1 + Reg group; 9) Compound 1 (90 mg / kg) and PD-1 + Reg group; 10) Control Compound (10 mg / kg) and PD-1 + Reg group; 11) Control Compound (30 mg / kg) and PD-1 + Reg group; 12) Control Compound (90 mg / kg) and PD-1 + Reg group, with 6 mice in each group. The results are shown in Table 12 below.
[0202] Table 12 In vivo efficacy of some compounds of the present invention in the CT-26 model
[0203] Note: Reg denotes regorafenib; PD-1 denotes anti-PD-1 antibody; IV denotes intravenous administration; PO denotes oral administration; QD denotes once-daily administration; QW denotes once-weekly administration; CR denotes complete remission (complete disappearance of the tumor after the completion of the dosing cycle); PR denotes partial remission (tumor volume is reduced by more than 30% relative to the initial volume after the completion of the dosing cycle); SD denotes stable disease (tumor volume is reduced or increased by no more than 30% relative to the initial volume after the completion of the dosing cycle); the dosing cycle is QD for 14 consecutive days, and QW is only administered on the 1st and 8th days.
[0204] The in vivo experimental results above demonstrate that the combination of the compounds of this invention with PD-1 and Reg exhibits a significant inhibitory effect against the CT-26 tumor model. In Group 7, tumors were significantly reduced in 50% (3 / 6) of mice, in Group 8, in 66.7% (4 / 6) of mice, and in Group 9, in 83.3% (5 / 6) of mice. Furthermore, at equivalent doses, the triple combination efficacy of the compounds of this invention was superior to that of the control compound.
[0205] Biological Example 8 Effect of the Compounds of the Present Invention on PBMC-Mediated Tumor Cell Killing
[0206] 4000 OVCAR 3 cells were seeded in a 96-well plate. After overnight attachment, serially diluted compounds were added and incubated for 72 hours. After staining the OVCAR 3 cells with Calcein AM, PBMCs were added and cultured for 1-4 hours. After washing with PBS, tumor cells were counted. The EC value of the compound for promoting cell death compared to DMSO was calculated. 50 .
[0207] Biological Example 9 Determination of the Effect of the Compounds of the Present Invention on Cellular PD-L1 Expression
[0208] 3000 MD-MBA 231 cells were seeded per well in a 96-well plate. After overnight adherence, serially diluted compounds were added. After 72 hours of treatment, cell surface PD-L1 expression was assessed by ELISA.
[0209] Although the above describes specific embodiments of the present invention, it should be understood by those skilled in the art that these are merely illustrative and that various changes or modifications may be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.
Claims
1. A compound represented by the general formula (1) or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates: In the general formula (1): X is -NH2, -OH; Cy is (C6-C14)aryl or (5-14 membered)heteroaryl, wherein the (C6-C14)aryl or (5-14 membered)heteroaryl may be independently optionally substituted by 1, 2, 3 or 4 R 5 replace; Ring A is (C6-C14)aryl, (5-14 membered)heteroaryl, (C3-C14)cycloalkyl or (3-14 membered)heterocycloalkyl; R 1 H, D, halogen; R 2 is H, D, halogen, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl; R 3 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl, wherein said (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl may be independently optionally substituted by 1, 2, 3 or 4 R a replace; R 4 is (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl; wherein the (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl can be independently substituted by 1, 2, 3 or 4 R b replace; or R 3 and R 4 The S atom to which it is connected forms a (3-16 membered) heterocycloalkyl group, wherein the (3-16 membered) heterocycloalkyl group may be independently optionally substituted with 1, 2, 3 or 4 R 6 replace; R 5 H, D, halogen, hydroxyl, amino, cyano, nitro, -OR a 、-NR a R b 、-C(O)R a 、-CO2R a 、-(CH2) m R a 、-(CH2) m CO2R a 、-(CH2) m -CONR a R b 、-S(O) p R a 、-S(O) p NR a R b 、-CONR a R b 、-C(=NR a )-NR a R b 、-NR a COR b , -CR a CONR a R b 、-NR a CO2R a 、-NR a S(O) p NR a R b 、-NR a S(O) p R a 、-P(O) p R a R b , (C1-C8) alkyl, (C1-C8) alkoxy, (C1-C8) haloalkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C14) cycloalkyl, (3-14 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C8) alkylene-(C3-C14) cycloalkyl, -(C1-C8) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C8) alkylene-(C6-C14) aryl, -(C1-C8) 8) alkylene-(5-14 membered) heteroaryl, wherein the (C1-C8) alkyl, (C1-C8) alkoxy, (C1-C8) haloalkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C14) cycloalkyl, (3-14 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C8) alkylene-(C3-C14) cycloalkyl, -(C1-C8) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C8) alkylene -(C6-C14)aryl, -(C1-C8)alkylene-(5-14 membered)heteroaryl may be independently optionally substituted with 1, 2, 3 or 4 R c replace; R 6 H, D, halogen, hydroxyl, amino, cyano, nitro, -OR a 、-NR a R b 、-C(O)R a 、-CO2R a 、-(CH2) m R a 、-(CH2) m CO2R a 、-(CH2) m -CONR a R b 、-S(O) p R a 、-S(O) p NR a R b 、-CONR a R b 、-C(=NR a )-NR a R b 、-NR a COR b , -CR a CONR a R b 、-NR a CO2R a 、-NR a S(O) p NR a R b 、-NR a S(O) p R a 、-P(O) p R a R b , (C1-C8) alkyl, (C1-C8) alkoxy, (C1-C8) haloalkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C14) cycloalkyl, (3-14 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C8) alkylene-(C3-C14) cycloalkyl, -(C1-C8) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C8) alkylene-(C6-C14) aryl, -(C1-C8) alkylene-(5-14 membered) heteroaryl, wherein the (C1-C8) 8) alkyl, (C1-C8) alkoxy, (C1-C8) haloalkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C14) cycloalkyl, (3-14-membered) heterocycloalkyl, (C6-C14) aryl, (5-14-membered) heteroaryl, -(C1-C8) alkylene-(C3-C14) cycloalkyl, -(C1-C8) alkylene-(3-14-membered) heterocycloalkyl, -(C1-C8) alkylene-(C6-C14) aryl, -(C1-C8) alkylene-(5-14-membered) heteroaryl may each independently be optionally substituted by 1, 2, 3 or 4 R c Replace; or when 2 R 6 When attached to the same atom, the two R 6 The atoms to which it is attached may form an oxo group, a (C3-C6) cycloalkyl group or a (3-6 membered) heterocycloalkyl group; R a and R b each is independently -H, -D, halogen, hydroxy, amino, cyano, nitro, (C1-C8) alkyl, (C1-C8) alkoxy, (C1-C8) haloalkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C14) cycloalkyl, (3-14 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C8) alkylene-(C3-C14) cycloalkyl, -(C1-C8) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C8) alkylene-(C6-C14) aryl, -(C1-C8) alkylene-(5-14 membered) heteroaryl wherein the (C1-C8)alkyl, (C1-C8)alkoxy, (C1-C8)haloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C14)cycloalkyl, (3-14-membered)heterocycloalkyl, (C6-C14)aryl, (5-14-membered)heteroaryl, -(C1-C8)alkylene-(C3-C14)cycloalkyl, -(C1-C8)alkylene-(3-14-membered)heterocycloalkyl, -(C1-C8)alkylene-(C6-C14)aryl, -(C1-C8)alkylene-(5-14-membered)heteroaryl may be independently optionally substituted by 1, 2, 3 or 4 R c Replace; or when 2 R a When attached to the same atom, the two R a can form an oxo group; or when 2 R b When attached to the same atom, the two R b can form an oxo group; or R a and R b The atoms to which it is attached together form a (5-7 membered) heterocycloalkyl or (C3-C9) cycloalkyl, wherein the (5-7 membered) heterocycloalkyl or (C3-C9) cycloalkyl are each independently optionally substituted by 1, 2, 3 or 4 R c replace; R c is -H, -D, halogen, hydroxy, amino, cyano, nitro, (C1-C8) alkyl, (C1-C8) alkoxy, (C1-C8) haloalkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C14) cycloalkyl, (3-14-membered) heterocycloalkyl, (C6-C14) aryl, (5-14-membered) heteroaryl, -(C1-C8) alkylene-(C1-C8) alkoxy, -(C1-C8) alkylene-(C3-C14) cycloalkyl, -(C1-C8) alkylene-(3-14-membered) heterocycloalkyl, -(C1-C8) alkylene-(C6-C14) aryl, -(C1-C8) alkylene-(5-14-membered) heteroaryl; or when 2 R c When attached to the same atom, the two R c It may form an oxo group, a (C3-C6) cycloalkyl group or a (3-6 membered) heterocycloalkyl group; m, n, and p are integers of 0, 1, or 2.
2. The compound according to claim 1 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), X is -NH2, -OH; X is preferably -NH2.
3. The compound according to claim 1 or 2, or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), ring A is (C6-C10)aryl, (5-10-membered)heteroaryl, (C3-C12)cycloalkyl or (3-12-membered)heterocycloalkyl; ring A is preferably phenyl, (5-7-membered)heteroaryl, (C5-C7)cycloalkyl; ring A is more preferably phenyl, pyridyl or cyclohexyl.
4. The compound according to any one of claims 1 to 3 or any of its isomers, crystalline forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), Cy is (C6-C10)aryl or (5-12 membered)heteroaryl, wherein the (C6-C10)aryl or (5-12 membered)heteroaryl may be independently optionally replaced by 1, 2, 3 or 4 R 5 Substitution; Cy is preferably phenyl, (5-7 membered) heteroaryl.
5. The compound according to claim 4 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), Cy is phenyl or (5-6 membered) heteroaryl, preferably 6. The compound according to claim 4 or 5, or any isomer, any crystalline form, any pharmaceutically acceptable salt, any hydrate or any solvate thereof, wherein in the general formula (1), R 5 H, D, halogen, hydroxyl, amino, cyano, nitro, -OR a 、-NR a R b 、-C(O)R a 、-CO2R a 、-(CH2) m R a 、-(CH2) m CO2R a 、-(CH2) m CONR a R b 、-S(O) p R a 、-S(O) p NR a R b 、-CONR a R b 、-C(=NR a )-NR a R b 、-NR a COR b , -CR a CONR a R b 、-NR a CO2R a 、-NR a S(O) p NR a R b 、-NR a S(O) p R a 、-P(O) p R a R b , (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C12) cycloalkyl, (3-12 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C6) alkylene-(C3-C14) cycloalkyl, -(C1-C6) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C6) alkylene-(C6-C14) aryl, -(C1-C6) alkylene-(5-14 membered) heteroaryl, wherein the (C1-C6) 6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C12) cycloalkyl, (3-12 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C6) alkylene-(C3-C14) cycloalkyl, -(C1-C6) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C6) alkylene-(C6-C14) aryl, -(C1-C6) alkylene-(5-14 membered) heteroaryl may each independently be optionally substituted by 1, 2, 3 or 4 R c Replacement; R 5 Preferably H, D, halogen, hydroxy, amino, cyano, nitro, -OR a 、-NR a R b 、-CONR a R b 、-P(O) p R a R b 、-S(O) p R a , (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C2-C4 alkenyl, (C2-C4) alkynyl, (C3-C7) cycloalkyl, (3-7 membered) heterocycloalkyl.
7. The compound according to claim 6 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 5 is H, D, F, Cl, -CN, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, (C3-C6) cycloalkyl, R 5 Preferably H, D, F, Cl, -CN, -CH3, -CF3, -OCH3 or 8. The compound according to any one of claims 1 to 7 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 1 For H, D, F, Cl, Br, I; R 1 Preferred are H, D and F.
9. The compound according to any one of claims 1 to 8 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 2 is H, D, F, Cl, Br, I, (C1-C3) alkyl, (C1-C3) alkoxy, (C1-C3) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl; R 2 Preferred are H, D and F.
10. The compound according to any one of claims 1 to 9 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 3 is (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl, wherein the (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl can be independently substituted by 1, 2, 3 or 4 R a Replacement; R 3 Preferably, it is (C1-C4) alkyl, (C1-C4) alkoxy, or (C1-C4) haloalkyl; R 3 More preferred are methyl, ethyl and methoxymethyl.
11. The compound according to any one of claims 1 to 10 or any isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, wherein in the general formula (1), R 4 is (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl, wherein the (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, (3-6 membered) heterocycloalkyl can be independently substituted by 1, 2, 3 or 4 R b Replacement; R 4 Preferably, it is (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl; R 4 More preferred are methyl, ethyl and methoxymethyl.
12. The compound according to any one of claims 1 to 9 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 3 and R 4 The S atom to which it is attached forms a (3-14 membered) heterocycloalkyl group, wherein the (3-14 membered) heterocycloalkyl group may be independently optionally substituted with 1, 2, 3 or 4 R 6 replace.
13. The compound according to claim 12 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 3 and R 4 The S atom to which it is connected forms a (4-6 membered) monocyclic heterocycloalkyl group containing 1 or 2 members selected from N, S or O, or a (7-9 membered) bicyclic spirocyclic heterocycloalkyl group containing 1 or 2 members selected from N, S or O, wherein the (4-6 membered) monocyclic heterocycloalkyl group or the (7-9 membered) bicyclic spirocyclic heterocycloalkyl group can be independently and optionally replaced by 1, 2, 3 or 4 R 6 replace.
14. The compound according to claim 12 or 13, or any isomer, any crystal form, any pharmaceutically acceptable salt, any hydrate or any solvate thereof, wherein in the general formula (1), R 6 H, D, halogen, hydroxyl, amino, cyano, nitro, -OR a 、-NR a R b 、-C(O)R a 、-CO2R a 、-(CH2) m R a 、-(CH2) m CO2R a 、-(CH2) m CONR a R b 、-S(O) p R a 、-S(O) p NR a R b 、-CONR a R b 、-C(=NR a )-NR a R b 、-NR a COR b , -CR a CONR a R b 、-NR a CO2R a 、-NR a S(O) p NR a R b 、-NR a S(O) p R a 、-P(O) p R a R b , (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C14) cycloalkyl, (3-14 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C6) alkylene-(C3-C14) cycloalkyl, -(C1-C6) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C6) alkylene-(C6-C14) aryl, -(C1-C6) alkylene-(5-14 membered) heteroaryl, wherein the (C1-C6) 6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C14) cycloalkyl, (3-14 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C6) alkylene-(C3-C14) cycloalkyl, -(C1-C6) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C6) alkylene-(C6-C14) aryl, -(C1-C6) alkylene-(5-14 membered) heteroaryl may each independently be optionally substituted by 1, 2, 3 or 4 R c Replacement; R 6 Preferred are H, D, halogen, hydroxyl, amino, cyano, -OR a 、-NR a R b , (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, -(C1-C4) alkylene-(C3-C7) cycloalkyl, -(C1-C4) alkylene-(3-7 membered) heterocycloalkyl, -(C1-C4) alkylene-(5-7 membered) heteroaryl, wherein the (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, -(C1-C4) alkylene-(C3-C7) cycloalkyl, -(C1-C4) alkylene-(3-7 membered) heterocycloalkyl, -(C1-C4) alkylene-(5-7 membered) heteroaryl can be independently optionally replaced by 1, 2, 3 or 4 R c Replace; or when 2 R 6 When attached to the same atom, the two R 6 The atom to which it is attached can form an oxo group.
15. The compound according to claim 14 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R 6 is H, D, F, Cl, hydroxyl, amino, cyano, methyl, ethyl, -NH(CH3), -N(CH3)2, -CD3, -C(O)CH3 or 16. The compound according to any one of claims 1 to 15 or any isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, wherein in the general formula (1), R a and R b Each is independently -H, -D, halogen, hydroxy, amino, cyano, nitro, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C14) cycloalkyl, (3-14 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C6) alkylene-(C3-C14) cycloalkyl, -(C1-C6) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C6) alkylene- (C6-C14)aryl, -(C1-C6)alkylene-(5-14 membered)heteroaryl, wherein the (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)haloalkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C14)cycloalkyl, (3-14 membered)heterocycloalkyl, (C6-C14)aryl, (5-14 membered)heteroaryl, -(C1-C6)alkylene-(C3-C14)cycloalkyl, -(C1-C6)alkylene-(3-14 membered)heterocycloalkyl, -(C1-C6)alkylene-(C6-C14)aryl, -(C1-C6)alkylene-(5-14 membered)heteroaryl can each be independently optionally replaced by 1, 2, 3 or 4 R c Replace; or when 2 R a When attached to the same atom, the two R a can form an oxo group; or when 2 R b When attached to the same atom, the two R b Can form an oxo group; R a and R b Each of them is independently preferably H, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C3-C7) cycloalkyl, (3-7 membered) heterocycloalkyl, (C6-C10) aryl, (5-7 membered) heteroaryl, wherein the (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C3-C7) cycloalkyl, (3-7 membered) heterocycloalkyl, (C6-C10) aryl, (5-7 membered) heteroaryl can be independently optionally replaced by 1, 2, 3 or 4 R c replace.
17. The compound according to any one of claims 1 to 15 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R connected to the same atom a and R b The atoms connected thereto together form a (5-7 membered) heterocycloalkyl or (C3-C9) cycloalkyl, wherein the (5-7 membered) heterocycloalkyl or (C3-C9) cycloalkyl is independently optionally substituted by 1, 2, 3 or 4 R c replace.
18. The compound according to any one of claims 1 to 17 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, wherein in the general formula (1), R c is -H, -D, halogen, hydroxy, amino, cyano, nitro, (C1-C6) alkyl, (C1-C6) alkoxy, (C1-C6) haloalkyl, (C2-C6) alkenyl, (C2-C6) alkynyl, (C3-C14) cycloalkyl, (3-14 membered) heterocycloalkyl, (C6-C14) aryl, (5-14 membered) heteroaryl, -(C1-C6) alkylene-(C1-C8) alkoxy, -(C1-C6) alkylene-(C3-C14) cycloalkyl, -(C1-C6) alkylene-(3-14 membered) heterocycloalkyl, -(C1-C6) alkylene-(C6-C14) aryl, -(C1-C6) alkylene-(5-14 membered) heteroaryl; or when 2 R c When attached to the same atom, the two R c Can form an oxo group; R c Preferred are H, D, halogen, hydroxy, amino, cyano, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, (C3-C7) cycloalkyl, (3-7 membered) heterocycloalkyl.
19. The compound according to claim 1-18 or its isomers, crystalline forms, pharmaceutically acceptable salts, hydrates or solvates, wherein the compound has one of the following structures:
20. A pharmaceutical composition, characterized in that It contains a pharmaceutically acceptable excipient or carrier, and the compound according to any one of claims 1 to 19 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates as active ingredients.
21. A pharmaceutical composition, characterized in that It contains a pharmaceutically acceptable excipient or carrier, and a therapeutically effective amount of a compound as described in any one of claims 1 to 19 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, and a therapeutically effective amount of an immune checkpoint inhibitor as active ingredients.
22. A pharmaceutical composition, characterized in that It contains a pharmaceutically acceptable excipient or carrier, and a therapeutically effective amount of a compound as described in any one of claims 1 to 19 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates, and a therapeutically effective amount of an immune checkpoint inhibitor and a therapeutically effective amount of a VEGFR inhibitor as active ingredients.
23. Use of the compound according to any one of claims 1 to 19 or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates or the pharmaceutical composition according to any one of claims 20 to 22 in the preparation of drugs for treating, regulating and / or preventing diseases associated with HDAC inhibitors.
24. The use according to claim 23, wherein the disease is cancer, and the cancer is blood cancer and solid tumor.
25. The use of claim 24, wherein the cancer comprises breast cancer, colon cancer, uterine cancer, pancreatic cancer, lung cancer, stomach cancer, blood cancer, lymphoma, prostate cancer, liver cancer, cervical cancer, neuroblastoma, melanoma or intracranial tumor.
Citation Information
Patent Citations
Bezimidazole derivatives as adenosine receptor antagonists
CN110997662A
Pyrazole derivatives as malt1 inhibitors
CN112601747A
Histone deacetylase inhibitor having nitrogen-containing aromatic heterocyclic group
EP4074700A1
N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-RAF inhibitors for the treatment of cancer
US20110003859A1
N- (6-aminopyridin-3-YL) -3- (sulfonamido) benzamide derivatives as b-RAF inhibitors for the treatment of cancer
WO2009111280A1
Cited By
HDAC inhibitor, composition and use thereof
WO2025131131A1
